In addition to ovarian and breast cancers, human prolactin is also associated with many other cancers.
80% of endometrial cancer patients are prolactin receptor positive and only chemotherapy drugs are approved for this disease. Accordingly, we believe Prolanta™ has significant potential to be used either alone where chemotherapy fails or in combination with chemotherapy. Furthermore, Prolanta has the potential to improve the efficacy of chemotherapy when taxane and/or platinum therapies are prescribed.
In early stage, a hysterectomy is often effective with surgery alone or in combination with radiation. In more advanced stages, radiation and chemotherapy are prescribed. Carbolatin is the platinum standard but cisplatin is also used. In addition to taxanes and platinum, ifosfamide (another chemotherapy agent) is prescribed.
Oncolix intends to sponsor additional sponsored research with MD Anderson to further determine the potential for Prolanta™ to treat endometrial cancer.
Many cervical cancer patients are prolactin receptor positive but the percentage is unknown. Preventative vaccines are on the market, including Cervarix and Gardasil. Patients are treated between the age of 9 and 26 to be effective (prior to sex). In addition to chemotherapy, radiation and bleomycin (an antibiotic) are used to treat cervical cancer.
Prolanta™ has significant potential to treat those patients that are prolactin receptor positive either alone or in combination with chemotherapy.
Other Potential Cancers
While the focus of Oncolix is gynecological and breast cancers, Prolanta has the potential to treat other cancers that have high expression levels of prolactin receptors. Potential indications include cancers of the Pancreas, Head & Neck, Prostate, Lung, Bladder and the Larynx.